Home › NDC Lookup › RxCUI directory › RxCUI 1992821

Ertugliflozin 15 MG Oral Tablet [Steglatro] — RxCUI 1992821

RxNorm drug concept · Semantic branded drug
RxCUI 1992821 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 9 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1992821
Official nameErtugliflozin 15 MG Oral Tablet [Steglatro]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asSteglatro 15 MG Oral Tablet
FDA products mapped2
Package NDCs mapped9
Reported Medicaid activity (SDUD)183,513 prescriptions · 28 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Ertugliflozin: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Steglatro helps lower your blood sugar by working through your kidneys. Normally, your kidneys filter sugar out of your blood and then reabsorb it back in. Steglatro blocks that re...
  • What exactly does Steglatro do for my diabetes?
  • Often yes, but it depends on what you're taking. If you use insulin or a sulfonylurea (a pill that makes your pancreas release more insulin), combining it with Steglatro raises you...
  • Can I take Steglatro with my other diabetes medications?
📖 Read our full Ertugliflozin guide →

🕸️ Concept Web — How Ertugliflozin 15 MG Oral Tablet [Steglatro] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Ertugliflozin 15 MG Oral Tablet [Steglatro] RxCUI 1992821

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Ertugliflozin 1992672
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Steglatro 1992811
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Ertugliflozin Oral Tablet 1992809
    • Ertugliflozin Oral Product 1992807
    • Ertugliflozin Pill 1992808
    • Ertugliflozin Oral Tablet [Steglatro] 1992813
    • Steglatro Oral Product 1992814
    • Steglatro Pill 1992815
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Ertugliflozin 15 MG Oral Tablet SCD · 1992819
  • Ertugliflozin 15 MG SCDC · 1992818
  • Ertugliflozin Oral Tablet SCDF · 1992809
  • Ertugliflozin Oral Product SCDG · 1992807
  • Ertugliflozin Pill SCDG · 1992808

Brand-Name Concepts

  • Ertugliflozin 15 MG [Steglatro] SBDC · 1992820
  • Ertugliflozin Oral Tablet [Steglatro] SBDF · 1992813
  • Steglatro Oral Product SBDG · 1992814
  • Steglatro Pill SBDG · 1992815
  • Steglatro BN · 1992811

📦 FDA Products & Package NDCs

2 products · 9 package NDCs
9 package NDCs map to RxCUI 1992821 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00006-5363-03 30 TABLET, FILM COATED in 1 BOTTLE (0006-5363-03) STEGLATRO Merck Sharp & Dohme LLC 2017-12-19
00006-5363-06 90 TABLET, FILM COATED in 1 BOTTLE (0006-5363-06) STEGLATRO Merck Sharp & Dohme LLC 2017-12-19
00006-5363-07 500 TABLET, FILM COATED in 1 BOTTLE (0006-5363-07) STEGLATRO Merck Sharp & Dohme LLC 2017-12-19
00006-5363-09 2 BOTTLE in 1 CARTON (0006-5363-09) / 7 TABLET, FILM COATED... STEGLATRO Merck Sharp & Dohme LLC 2017-12-19
00006-5363-10 30 TABLET, FILM COATED in 1 BOTTLE (0006-5363-10) STEGLATRO Merck Sharp & Dohme LLC 2017-12-19
00006-5364-03 30 TABLET, FILM COATED in 1 BOTTLE (0006-5364-03) STEGLATRO Merck Sharp & Dohme LLC 2017-12-19
00006-5364-06 90 TABLET, FILM COATED in 1 BOTTLE (0006-5364-06) STEGLATRO Merck Sharp & Dohme LLC 2017-12-19
00006-5364-07 500 TABLET, FILM COATED in 1 BOTTLE (0006-5364-07) STEGLATRO Merck Sharp & Dohme LLC 2017-12-19
00006-5364-09 2 BOTTLE in 1 CARTON (0006-5364-09) / 7 TABLET, FILM COATED... STEGLATRO Merck Sharp & Dohme LLC 2017-12-19
Observed labelers: Merck Sharp & Dohme LLC (9) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.